Dutasteride with as-needed tamsulosin in men at risk of benign prostatic hypertrophy progression

UroToday International Journal

Volumn 5, Issue 1, 2012, Pages

  Siami, Paul F ^a   Beasley, Knox ^a  

^a Research Institute of Deaconess Clinic   (United States)

Author keywords

Benign prostatic hyperplasia; Dutasteride; Tamsulosin

Indexed keywords

EID: 84856582636     PISSN: None     EISSN: 19394810     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008;179(2):616-612. PubMed; CrossRef
2. Emberton M, Cornel EB, Bassi PF, et al. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract. 2008;62(7):1076-1086. PubMed; CrossRef
3. Kirby RS, Roehrborn P, Boyle P, Bartach G, et al. Efficacy and tolerability of doxazocin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazocin and Combination Therapy (PREDICT) trial. Urology. 2003;61(1):119-126. PubMed; CrossRef
4. Lepor H, Williford WO, Barry MJ, et al. The effects of Terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Eng J Med. 1996;335(8):533-539. PubMed; CrossRef
5. McConnel JD, Roehrborn CG, Bautista OM, et al. The long term effect of doxazosin, finasteride, and combination therapy on clinical progression of BPH. N Engl J Med. 2003;349(25):2387-2398. PubMed; CrossRef
6. Barkin J, Guimarães M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol. 2003;44(4):461-466. PubMed; CrossRef